Back

Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

2 September 2019 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 6 Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Hendrik Bonnemeier

Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)

9 More presentations in this session

Presentation thumbnail
Mr J. Choi (Busan, KR)
Abstract Slides
Presentation thumbnail
Doctor J. Strange (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Doctor T. Chao (Taipei, TW)
Abstract
Presentation thumbnail
Ms A. Kang (Princeton, US)
Abstract Slides
Presentation thumbnail
Doctor C. Boerschel (Hamburg, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

The Event

Event poster

ESC Congress 2019

2 September 2019 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries
2 September 2019
thumbnail
Congress Presentation
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
1 September 2025
thumbnail
Congress Presentation
Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
30 August 2020
thumbnail
Congress Presentation
Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin
25 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources